Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
Businesswire·2026-07-13 20:32

公司动态 - Niagen Bioscience公司宣布其领先候选药物NB4168获得美国食品药品监督管理局授予的罕见儿科疾病认定，该药物用于治疗共济失调毛细血管扩张症 [1] - NB4168是一种口服小分子疗法，旨在递送显著更高水平的烟酰胺腺嘌呤二核苷酸前体 [1] 产品与研发 - 公司的核心研究领域聚焦于烟酰胺腺嘌呤二核苷酸与健康衰老的科学 [1] - 获得认定的候选药物NB4168是公司专有的领先小分子药物 [1]

Rapid7-Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) - Reportify